(19)
(11) EP 2 487 189 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 2 (W2 B1)

(48) Corrigendum issued on:
09.01.2019 Bulletin 2019/02

(45) Mention of the grant of the patent:
22.08.2018 Bulletin 2018/34

(21) Application number: 12003416.0

(22) Date of filing: 14.03.2008
(51) International Patent Classification (IPC): 
C07K 16/30(2006.01)
A61P 35/00(2006.01)
 A61K 39/395(2006.01)

(54)

MONOCLONAL ANTIBODIES AGAINST GT468 FOR TREATMENT OF CANCER

MONOKLONALE ANTIKÖRPER GEGEN GT468 ZUR BEHANDLUNG VON KREBS

ANTICORPS MONOCLONAUX CONTRE GT468 POUR LE TRAITEMENT DU CANCER

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA MK RS

(30) Priority: 14.03.2007 EP 07005258
14.03.2007 US 894860 P

(43) Date of publication of application:
15.08.2012 Bulletin 2012/33

(62) Application number of the earlier application in accordance with Art. 76 EPC:
08734614.4 / 2125897

(73) Proprietors:
  • Astellas Pharma Inc.
    Chuo-ku Tokyo 103-8411 (JP)
  • TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
    55131 Mainz (DE)

(72) Inventors:
  • Sahin, Ugur
    55116 Mainz (DE)
  • Koslowski, Michael
    85764 Oberschleißheim (DE)
  • Türeci, Özlem
    55116 Mainz (DE)

(74) Representative: Schnappauf, Georg et al
ZSP Patentanwälte PartG mbB Hansastraße 32
80686 München
80686 München (DE)


(56) References cited: : 
EP-A- 1 762 575
US-A1- 2002 065 394
 WO-A-03/075014
   
  • CHEN JING ET AL: "[PLAC1/CP1 gene expression and autologous humoral immunity in gastric cancer patients]", BEIJING DA XUE XUE BAO. YI XUE BAN = JOURNAL OF PEKING UNIVERSITY. HEALTH SCIENCES 18 APR 2006, vol. 38, no. 2, 18 April 2006 (2006-04-18) , pages 124-127, XP009085470, ISSN: 1671-167X
  • KOSLOWSKI MICHAEL ET AL: "A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 67, no. 19, 1 October 2007 (2007-10-01), pages 9528-9534, XP002471063, ISSN: 0008-5472
  • DONG XUE-YUAN ET AL: "PLAC1 is a tumor-specific antigen capable of eliciting spontaneous antibody responses in human cancer patients", INTERNATIONAL JOURNAL OF CANCER, vol. 122, no. 9, May 2008 (2008-05), pages 2038-2043, XP009102971, ISSN: 0020-7136
  • COCCHIA M ET AL: "PLAC1, an Xq26 Gene with Placenta-Specific Expression", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 68, no. 3, 15 September 2000 (2000-09-15), pages 305-312, XP004437833, ISSN: 0888-7543
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).